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The immune contexture of 
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The general relevance of the immune system for cancer development and therapy is increasingly 
recognized. However and although the immune contexture of most human cancer types has been 
determined, a global characterisation of the immune tumour microenvironment in hepatocellular 
carcinoma (HCC) is lacking. Equally, differences in the immune contexture of HCC between different 
patient subgroups and its effect on survival remain to be established. Here we report an in silico analysis 
of the immune contexture of human HCC. Using large deep sequencing HCC tumour, adjacent non-
tumour and healthy liver high-dimensional data sets, we were able to reveal previously unrecognized 
differences in the immune contexture of HCC. Strikingly, we found that different etiologies and HCC 
stages were not associated with major changes in the immune contexture. In contrast, the presence 
of T cells and cytotoxic cells as well as the absence of macrophages and Th2 cells positively correlated 
with patient survival. Based on these novel findings, we developed a prognostic score that accurately 
distinguishes between patients with good and poor survival. Our study provides the first global 
characterisation of the immune contexture of HCC and will have direct implications for future HCC 
therapies.
Hepatocellular carcinoma (HCC) is one of the most frequent and lethal human cancers, and its incidence is 
rising1,2. HCC has an overall dismal prognosis and only when diagnosed early, surgery and ablative therapies 
may offer a cure3. In most cases, however, HCC is diagnosed at an advanced stage, when multi tyrosine kinase 
inhibitors (sorafenib4 or regorafenib5) and most recently the immune checkpoint inhibitor nivolumab6,7 or best 
supportive care remain the only available treatment options. To develop more effective therapies and to identify 
factors that determine patient survival, a better mechanistic understanding of HCC is urgently needed.
The immune system strongly influences cancer development8,9. Compelling evidence indicates that tumours 
evade destruction by suppressing the host’s immune system10. It is now generally accepted that tumour-immune 
cell interactions are highly relevant for patient survival and that the immune contexture of tumours represents a 
therapeutic target for improving clinical outcome9,11–14. Since HCC typically arises in the background of chronic 
inflammation (caused by alcohol consumption, virus infections or non-alcoholic fatty liver disease)15, it will be 
crucial to understand the pro- and anti-tumour function of the immune system in a chronically inflamed but 
tumour-tolerant microenvironment. So far, studies on the immune tumour microenvironment (TME) of HCC 
have been limited to biochemical, flow cytometric or microscopic methodologies that are often cumbersome and 
only provide information about a reduced number of markers16–19. By contrast, next generation bioinformatics 
analysis of high-dimensional deep sequencing data offers the unique opportunity to comprehensively analyse 
transcriptional immune-regulatory networks and to accurately determine the different immune cell types that 
invade the TME. Using next generation bioinformatics, several papers reported the effect of the tumour immune 
contexture on patient survival for most human cancers11–13. Strikingly and although HCC is one of the major 
human cancer malignancies, a comprehensive immunome analysis for HCC is still missing. Equally, it remains 
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unknown whether overall immune cell numbers or the infiltration of specific immune cell types predict patient 
survival in HCC. Moreover and central to stratifying future treatment regimes, it is completely unknown if 
human HCCs of different etiology and stage differ in their immune TME. To guide current immune therapy trials 
and to improve future treatment options, detailed insight into the relationship between immune cell infiltration 
and clinical outcome will be needed20,21.
Combining high-throughput RNA-sequencing (RNA-Seq) HCC patient data with next generation bioinfor-
matics, we here report the first in silico immunome characterisation of human HCC. The results of this analysis 
clearly demonstrate that the nature and composition of tumour-infiltrating immune cells predict patient survival.
Results
Patient characteristics. We assembled individual transcriptomes from HCC and matched non-tumour 
samples using RNA-Seq data from The Cancer Genome Atlas (TCGA)22. After manually curating all data with 
respect to relevant clinical parameters (gender, ethnicity, etiology, tumour stage, performance, liver function and 
survival), 371 HCC tumour samples (HCC-T) and 50 matched non-tumour samples (HCC-NT) were included in 
the analysis. The majority of the selected patients were male (68% male/32% female) and Asian or Caucasian (45% 
and 49%, respectively). The most common disease etiology was hepatitis B (32%) followed by alcohol consump-
tion (25%) and hepatitis C (11%). According to the classification of malignant tumours (TNM classification), half 
of the patients had HCC stage I (49%), one quarter stage II (25%) and one quarter stage III or IV (26%). 90% of 
patients were R0-resected (no cancer cells at the resection margin) and in 5%, residual tumour (R1 (microscopic 
positive margin); and R2 (macroscopic positive margin)) was found in the resection margins. Two thirds (70%) 
had unaffected regional lymph nodes and three quarters (73%) were free of distant metastasis, while lymph node 
or distant metastasis were detected in only 1% each. Two thirds (65%) were free of vascular invasion, one third 
(30%) had micro-vascular and only a minority (5%) macro-vascular invasion. 87% of patients had a good or very 
good Eastern Cooperative Oncology Group (ECOG) performance status (ECOG 0 and 1) and 91% unimpaired 
liver function (Child-Pugh-Score A). The clinical characteristics of all patients as provided by TCGA are listed in 
Supplementary Table 1.
Although HCCs are surrounded by hyper-inflamed T helper cell 1 (Th1)-type non-tumour liver 
tissue, the tumour microenvironment is Th2-skewed and shows strongly reduced cytolytic and 
antigen presenting activity. High-throughput cancer studies usually compare tumour tissue to matched 
non-tumour samples from the same patients. To evaluate if inclusion of an additional reference group consisting 
of healthy liver tissue samples provides the opportunity to increase the statistical resolution between tumour and 
adjacent non-tumour tissue, we included 34 healthy liver (HL) RNA-Seq data sets from The Genotype-Tissue 
Expression (GTEx) project23 in our analysis (Fig. 1A). Combined evaluation of all three groups using princi-
pal component analysis (PCA) revealed the partial overlap between tumorous HCC (HCC-T) and adjacent 
non-tumour (HCC-NT) transcriptomes and demonstrated that HL samples formed a separate cluster (Fig. 1B).
Mediating the concern of a potential batch effect when comparing GTEx and TCGA data, the distribution of 
aligned reads over all genes appeared very similar in the TCGA and the GTEX data (Supplementary Figure S1). 
Since our main focus was on the expression of immune cell type-specific marker genes, we restricted the expres-
sion data to these genes and performed additional PCA. We did not observe a partitioning of the three sample 
classes (HCC-NT, HCC-T, HL) on the level of the principal component PC1 that explained the largest amount 
of variation (23.5%; Supplementary Figure S2). In contrast, the variance components that explained a smaller 
amount of variation (PC2-5; 10–3.4%) led to a distinct clustering of the samples. These findings exclude the pres-
ence of a major batch effect interfering with our analysis.
Pearson’s correlation analysis furthermore indicated the highest transcriptional divergence (R = 0.91) between 
HL and HCC-T, whereas HL and HCC-NT transcriptomes had a smaller correlation-based distance (R = 0.93) 
and HCC-T and HCC-NT were most similar (R = 0.97) (Supplementary Figure S3). Comparison of common and 
differentially expressed genes documented that the majority of transcripts were commonly expressed in all three 
groups (11,899) and identified 1,889 uniquely expressed transcripts for HCC-T, 6 for HCC-NT and 38 for HL 
samples (Fig. 1C and Supplementary Table 2). As shown in Fig. 1D, statistically significant transcriptome changes 
(FDR < 0.01; log2 FC > 2 and <−2) were more abundant between HCC-T and HL (2,648 transcripts) followed 
by HCC-NT and HL (1,874 transcripts) and HCC-T and HCC-NT (1,209 transcripts). These results document 
that patient-derived HCC-T and HCC-NT transcriptomes were much closer related to each other than patient 
and HL transcriptomes. To exclude that the proximity between HCC-T and HCC-NT transcriptomes negatively 
affects the overall resolution and to reveal shifts in immune cells and immune activities with regard to healthy 
liver tissues, we chose to utilize all three data sets for our analysis.
To gain insight into different immune cell subpopulations infiltrating HCCs and surrounding non-tumour 
tissues and to study immune effector activity within these two sites, we resorted to recently published human 
immune cell-specific gene sets11,13. Based on these gene sets and using RNA-Seq data from HCC-T, HCC-NT 
and HL, we devised an immune cell-type marker enrichment approach. Specifically, we calculated the infiltration 
of 24 different immune cell types and determined the activity of eight mechanistic immune functions that are 
linked to efficient anti-tumour immune responses (antigen presentation, cytolytic activity, interferon signalling 
and co-stimulation or co-inhibition of T and antigen presenting cells (APCs)). Consistent with the fact that liver 
cancer usually arises in a hyper-inflamed tissue context and that immune surveillance is often reduced in solid 
tumours, we found that most immune cell types such as B and T lymphocytes, NK (natural killer) cells, APCs, 
mast cells and granulocytes were more abundant in the surrounding liver tissue than in HCCs (Fig. 2A, HCC-T 
vs. HCC-NT). However, HCCs had more T helper, Th2 and plasmacytoid dendritic cells than the surrounding 
tissue. With respect to immune activity, marker enrichment analysis revealed that HCCs had more major his-
tocompatibility complex class I (MHC I) gene expression and increased T cell co-stimulation but less cytolytic 
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activity, less co-inhibition of T cells and APCs and less type I as well as type II interferon response. Interestingly, 
comparison between HCC-T vs. HL samples established that most immune cell types either were reduced in or 
not changed between HCCs and healthy livers. However, HCCs contained more Th2 cells, regulatory CD4+ T 
Figure 1. Transcriptomes from HCC and surrounding tissue are more closely related to each other than to 
healthy liver. (A) Schematic representation of data acquisition and analysis. Messenger RNA levels from HCC 
(371 patients), matched surrounding tissue (50 patients) and healthy livers (34 individuals) were obtained from 
The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression project (GTEx). (B) Differentiation 
of gene expression between HCC (HCC-T), tissue adjacent to HCC (HCC-NT) and healthy liver samples (HL). 
Samples are plotted based on their scores for the two variance components that explained most of the overall 
gene expression variation. The variance components were determined by a principal component analysis (PCA) 
conducted with the log-transformed aligned reads per gene. (C,D) Venn diagram (C) and MA-plots (D) showing 
differential gene expression from the three major inter-group comparisons (HCC-T vs. HCC-NT; HCC-T vs. HL; 
HCC-NT vs. HL). For MA-plot construction, a gene was considered to be differentially expressed between groups 
at an absolute log2 FC > 2 or <−2 and a FDR of 1% (moderated t-test; Benjamini-Hochberg procedure).
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cells, activated and plasmacytoid dendritic cells, and macrophages than normal livers. Finally, we calculated dif-
ferences in the immune contexture between HCC-NT and HL samples. This analysis documented that in tissues 
surrounding HCC, immune cell subsets required for an effective cytotoxic anti-cancer response such as T cells, 
CD8+ T cells, cytotoxic cells (representing CD8+ T cells, Tγδ and NK cells), Th1 cells, Tγδ cells and APCs were 
highly increased (Fig. 2A, HCC-NT vs. HL). Likewise and confirming the Th1-like immune activation pattern in 
tumour-adjacent patient samples, MHC I gene expression, cytolytic activity and type I and II interferon response 
all were strongly augmented (Fig. 2A, HCC-NT vs. HL).
These findings demonstrate a well-defined immune cell compartmentalization between HCCs and surround-
ing non-tumour tissues. While T helper and in particular, Th2 cells increased in HCCs, immune cells critical for 
an effective anti-cancer response, such as Th1-specific T cells, cytotoxic cells and dendritic APCs, were reduced. 
Our analysis thus delineates a very clear picture of the immune contexture of HCC and reveals that HCC is 
characterised by Th2-skewed tumours with low cytolytic and antigen-presenting activity, which are in turn sur-
rounded by Th1-type hyper-inflamed liver tissue.
The determination of global transcriptome changes between HCC-T, HCC-NT and HL also provides the 
opportunity to identify specific pathways that are deregulated in each tissue set. To gain more insight into the 
deregulation of immune response-related programs, transcripts from all three groups were subjected to Ingenuity 
Pathway Analysis (IPA®). IPA® validation unveiled that inclusion of HL samples facilitated the discovery of path-
ways that were deregulated in both HCCs and surrounding liver tissues. For example, when comparing HCC-T 
Figure 2. Healthy livers are a critical reference group for identifying differentially regulated immune cell 
types and pathways in HCC. (A) A gene set enrichment analysis was performed to detect coordinated changes 
of gene expression in gene sets of immune cell type-specific marker genes. Three inter-group comparisons 
were performed (HCC-T vs. HCC-NT; HCC-T vs. HL; HCC-NT vs. HL). Colour intensity reflects the log10 
transformed p-value from the enrichment analysis. Magenta colour indicates higher expression compared to the 
reference group while cyan colour indicates weaker expression compared to the reference group. (B,C) Selected 
immune pathways from an IPA® on the three major inter-group comparisons (B) activated pathways shared by 
HCC-T and HCC-NT; (C) pathways activated in either HCC-T or HCC-NT).
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vs. HCC-NT samples, the deregulation of pathways responsible for antigen presentation, dendritic cell matu-
ration, phagosome maturation and T helper cell differentiation was not detected. By contrast, when we applied 
IPA® to HCC-T vs. HL or HCC-NT vs. HL RNA-Seq data, all four pathways had high activation scores (Fig. 2B 
and Supplementary Figure S4). This indicates that the gene activity of major constituents of these pathways is sig-
nificantly increased in both HCC and surrounding non-tumour tissues. Applying IPA® to HCC-T and HCC-NT 
samples also revealed several immune regulatory differences between these two sites. For example, HCC-NT 
exhibited strong IL-17A/IL17F-dependent activation of macrophage and T helper cell cytokine production and 
an increase in IL-6 signalling in comparison to HCC-T (Fig. 2C and Supplementary Figure S5). Directly in line 
with the increased infiltration of different cytolytic and antigen presenting cells in tissues surrounding HCC, 
IPA® detected higher activity of pathways responsible for the communication between innate and adaptive cells 
in HCC-NT samples that was not apparent in HCC-T or HL. Also directly confirming previous marker enrich-
ment results, IPA® recorded the up-regulation of interferon signalling in tumour surrounding tissues in compar-
ison to healthy livers (Fig. 2C and Supplementary Figure S6). We thus conclude that pathways regulating antigen 
presentation, dendritic cell maturation, phagosome maturation and T helper cell differentiation are upregulated 
in both HCCs and surrounding non-tumour tissues.
Analysis of the immune contexture in different HCC risk factor groups and tumour stages. To 
investigate the immune TME in different HCC etiologies, we divided 371 TCGA patient samples into six groups 
consisting of patients with no risk factor, alcohol abuse, hepatitis B, hepatitis C, hepatitis and alcohol abuse and 
non-alcoholic steatohepatitis (NASH) (Supplementary Table 3). Using healthy liver samples as a reference group, 
we next applied the immune cell type marker enrichment analysis. As shown in Fig. 3A, B lymphocytes, cytotoxic 
cells, T follicular helper, Th 17 and Tγδ cells as well as NK cell subsets, mast cells, neutrophil and eosinophil 
granulocytes and also type II interferon response and co-inhibition of T and APC cells were decreased across all 
HCC etiologies when compared to healthy liver tissues. In contrast, all HCC samples contained more Th2 cells, 
Figure 3. HCC etiology and tumour stage are not linked to major changes in the immune contexture. (A,B) 
Immune cell type marker enrichment analysis to compare gene expression between HCC samples grouped for 
etiology (A) and tumour stage (B). HL was used as the reference group.
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plasmacytoid and activated dendritic cells as well as macrophages and exhibited increased MHC I gene expres-
sion and type I interferon response than normal livers. With regard to all other classifiers and with the exception 
of a few deviations in the alcohol abuse and NASH groups, no or only subtle differences were recorded across all 
six HCC etiologies. The lack of major changes in immune cell infiltration and immune activity patterns across 
HCCs of different etiology is likely to reflect a shared general characteristic of HCC to adapt a TME containing 
reduced numbers of immune cells and exhibiting less cytolytic, Type II interferon and co-stimulatory/-inhibitory 
pathway activity patterns.
To next determine whether differences in immune cell infiltration are associated with different HCC disease 
stages, we calculated the enrichment of different immune cell subsets using samples from early (stage I), inter-
mediate (stage II) and late stage (stage III and IV) HCC patients. While 18 immune cell types showed no good 
correlation with the analysed tumour stages, the marker enrichment analysis revealed reduced numbers of T cells, 
CD8+, Th1 as well as CD4+ regulatory T cells and dendritic cells in samples from more advanced HCC patients 
(Fig. 3B). With regard to immune activity patterns, late stage tumours exhibited less cytolytic activity, less type I 
interferon responses and reduced co-stimulation of T cells and APCs. Conversely, late stage tumours contained 
more T helper and Th2 cells. We conclude that HCC progression entails a gradual loss of anti-cancer immune sur-
veillance potential with late stage HCCs having a T helper cell-dominated and a Th1 anergic TME and a reduced 
ability to support Th1, cytolytic and Type I interferon signalling activities.
The immune contexture of HCC is associated with patient survival. The infiltration of solid 
tumours with T cells, APCs and innate immune cells and the presence of immune activities have been directly 
linked to patient survival in various cancers11–13. To investigate the association between the infiltration by differ-
ent immune cells and clinical outcome, we compared the tumour immune contextures of samples from patients 
with good (survival > 5 years,), intermediate (survival between 2 and 5 years) and poor outcome (survival < 2 
years). To avoid outliers produced by direct post-surgery effects, data sets of patients who died within 30 days 
after surgery were excluded. Notably, we observed considerable differences across the three groups and particu-
larly between patients with favourable and poor survival (Fig. 4A). Generally, infiltration by immune effector cells 
such as T cells, CD8+ T cells, Tγδ cells and NK cells was increased in samples from patients with good survival 
relative to those with poor survival.
In order to identify statistically significant associations with survival, we performed a Cox regression on the 
expression of immune cell type marker gene sets and survival data (Fig. 4B). A variety of immune cells including 
T cells, CD8+ as well as cytotoxic cells and NK cells were positively, while T helper/Th2 cells, immature dendritic 
cells and macrophages were negatively associated with survival (p < 0.05). After adjustment for multiple testing, 
T cells, cytotoxic cells, Th2 cells and macrophages were associated at a family-wise error rate (FWER) of 5%. 
Likewise and although MHC class I expression was not associated with survival, immune defence activity pat-
terns such as cytolytic activity and co-stimulation of T cells were positively associated with survival. From this 
analysis, we conclude that HCCs bearing increased numbers of adaptive and innate immune cell subsets and sup-
porting a Th-1-type immune response have a favourable survival. Conversely, intra-tumour invasion of Th2 cells 
and macrophages are inversely associated with patient survival. Of note is also that a similar pattern was obtained 
when an unrelated HCC patient cohort24 was analysed in the same way (Supplementary Figure S7).
A prognostic immune signature for HCC. Having demonstrated that the HCC immune contexture is 
linked to clinical outcome, we sought to establish a prognostic immune gene signature that distinguishes between 
groups with distinctly different survival. To this end, we combined the previously established four significant gene 
sets from the Cox regression analysis to a common immune gene signature (T cells, cytotoxic cells, Th2 cells and 
macrophages, genes listed in Supplementary Table 4). Application of this 89 immune gene signature divided the 
TCGA HCC cohort into patients with poor and favourable survival (Fig. 5A; hazard ratio [HR] for “poor”: 3.033; 
95% confidence interval [CI], 1.918 to 4.797; p < 0.0001). Directly confirming the predictive power of the estab-
lished immune gene signature, analysis of an unrelated HCC patient cohort24 also accurately predicted patient 
survival (Fig. 5B; hazard ratio [HR] for “poor”: 2.704; 95% confidence interval [CI], 1.126 to 6.495; p = 0.021). In 
addition, when we restricted the signature to gene sets specific for T cells, cytotoxic cells and macrophages, this 
score performed even better (64 genes; Supplementary Figure S8, genes listed in Supplementary Table 4).
In order to compare our gene signature with the hitherto state of the art, we tested three previously published 
gene sets: First, we applied the CIBERSORT algorithm25 to our TCGA patient dataset. Application of CIBERSORT 
to TCGA HCC samples (which was not done in the original pan-human cancer study by Gentles et al.12) and 
using a resampling test (for details see25), CIBERSORT reported that only 81 of 405 tested HCC and liver samples 
contained any type of immune cells (Supplementary Figure S9). Since it is not likely and plausible that 80% of 
the TCGA samples do not contain any immune cells, we did not consider the CIBERSORT method as a valuable 
approach for analysing HCC samples. Second, we applied two prognostic immune signatures previously pub-
lished by Chew et al.16,26 to the TCGA data set. Both signatures reached a lower significance level (Supplementary 
Figure S10; hazard ratio [HR] for “poor”: 1.795; 95% confidence interval [CI], 1.149 to 2.803; p = 0.009216 and 
hazard ratio [HR] for “poor”: 1.83; 95% confidence interval [CI], 1.175 to 2.848; p = 0.006726) in comparison to 
our immune signature indicating a stronger association of our gene set with survival (Fig. 5A). Finally, we tested 
an immune classifier set of 108 genes used to classify HCC tumour immune milieus that was published during 
the revision of our paper27. This signature achieved similar significance levels to predict survival (Supplementary 
Figure S10; hazard ratio [HR] for “poor”: 2.71; 95% confidence interval [CI], 1.706 to 4.304; p < 0.0001).
These results clearly demonstrate that the 89 and the 64 immune gene signatures have general utility for prog-
nostic HCC stratification suggesting that RNA-Seq data analysis of patient biopsies with these signatures can be 
directly used to guide future targeted and/or immune therapies.
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Discussion
Next generation bioinformatics analysis of high-dimensional data sets is increasingly used for the comprehen-
sive and unbiased characterisation of cancer TMEs and provides the opportunity to precisely characterise the 
infiltration of different immune cell types and immune activity patterns within tumours11–13. Here we report the 
first comprehensive bioinformatics analysis of the immune TME for human HCC. Our results demonstrate that 
different HCC etiologies and stages are not associated with major changes in the immune contexture and reveal 
that the nature and composition of tumour-infiltrating immune cells correlate with patient survival.
Strikingly and although next generation bioinformatics have been extensively used for characterising the 
immune TME of most major human malignancies11–13, no comprehensive immunome analysis for HCC has been 
published. Equally, it has been completely unknown if different HCC etiologies or disease stages have different 
immune contextures. And most importantly, it has still remained to be established whether the immune contex-
ture of HCC correlates with patient survival. Interestingly, the excellent bioinformatics analysis by Gentles and 
colleagues12, which covers all major human cancer subtypes, did not include human HCC, and the CIBERSORT 
tool that was developed in this study to predict patient survival did not produce plausible results when we used 
this algorithm on human TCGA HCC data. To close this gap and to provide detailed insight into the immune 
TME of human HCC, we established a straightforward bioinformatics approach and applied this methodology 
to human HCC integrating data from tumour samples, surrounding non-cancerous tissues and healthy livers.
Historically, most cancer studies compared tumour tissue to matched non-tumour samples from the same 
patient. By comparing patient-derived (HCC-T and HCC-NT) with healthy liver (HL) samples, we found that 
the transcriptomes of tumour and surrounding tissue samples formed partially overlapping clusters having close 
transcriptional proximity, while healthy liver probes clustered separately and were transcriptionally less related 
Figure 4. Survival of HCC patients depends on the immune contexture. (A) Immune cell type marker enrichment 
analysis to compare gene expression between HCC samples grouped for survival. Increased expression of marker 
genes for T cells, CD8+ T cells, CD4+ regulatory T cells, dendritic cells, cytolytic activity and T cell co-stimulation 
was observed in patients with favourable survival. HL was used as the reference group. (B) Association of immune 
cell type marker gene expression with survival. For each immune cell marker gene, association with survival in the 
TCGA data was estimated by Cox proportional hazards models. The distribution of z-scores per cell type category 
is shown in a boxplot. For each cell type category, consistent association of marker gene expression with survival 
was assessed. Marker gene sets for T cells, cytotoxic cells, Th2 cells and macrophages were significantly associated 
with survival at a family-wise error rate (FWER) of 5% indicated by “*” and coloured characters. These gene sets 
were combined to build a prognostic score (Fig. 5). Blue = higher expression corresponds with shorter survival, 
brown = higher expression corresponds with longer survival. The number of genes within a gene set and the 
p-value from the test of consistent association with survival (in vertical bars) are indicated for each cell type.
www.nature.com/scientificreports/
8SCIEnTIFIC REPoRTS |  (2018) 8:5351  | DOI:10.1038/s41598-018-21937-2
to HCC-T and HCC-NT patient samples. Regarding potential and unwanted batch effects arising during the 
comparison of different sample groups (HCC-T, HCC-NT and HL), both analysis of the overall distribution of the 
number of aligned reads per gene between the three groups and a PCA on the level of immune cell marker gene 
expression demonstrated the absence of major batch effects.
Highlighting that the inclusion of non-patient healthy liver tissue samples as a reference group provided 
additional advantages, we were able to uncover common immune-related switches shared between HCC-T and 
HCC-NT that would not have been identified by comparing tumours with adjacent non-tumour tissues. The partial 
overlap and close proximity of patient-derived HCC-T and HCC-NT samples and the opportunity to reveal mRNA 
expression patterns that are common to patient-derived probes but absent from healthy tissues highlights that the 
analysis of high-dimensional sequencing data greatly benefits from the inclusion of healthy tissue samples.
The first important feature emerging from our analysis is that HCC liver tissues are immunologically compart-
mentalized into immune compromised tumour areas that are surrounded by hyper-inflamed non-tumour tissues. 
Comparison of patient-derived and healthy samples clearly demonstrated that most immune cell subsets required 
for an efficient anti-tumour immune response were decreased in tumour samples when compared to tumour 
surrounding areas and also with regard to healthy livers. By contrast, gene signatures defining T helper and Th2 
cells were strongly increased in HCCs. Together with the low cytolytic and type I and type II interferon signalling 
activity recorded in HCC samples, these results reveal that HCC consists of a highly compromised, Th2-skewed 
immune milieu that lacks sufficient Th1-specific and cytolytic immune properties. Because targeted therapies 
and in particular immune therapies can be assumed (at least to some extent) to depend on the composition of the 
immune TME, additional research is required to investigate if such strategies can indeed modulate the immune 
contexture of HCC and thus enhance the potential of cancer therapies.
Previous studies on the global transcriptome of HCC have proposed molecular classifications based on gene 
expression profiling and exhibited correlation between distinct molecular subclasses and clinical parameters28,29. 
However, while clinical TNM-based and molecular features have been traditionally used to stratify different 
tumour subtypes, stages and clinical outcome, emerging evidence suggests that the immune contexture might be 
very useful or even superior for classifying tumour types and stages and for predicting patient survival9,11–14,30. 
Although we found no major changes in the immune TME of HCCs with different etiologies, our data strongly 
support the view that the HCC immunome is an excellent classifier for predicting patient survival. Indeed gene 
set enrichment analysis of HCC patient data established that the immune contexture of HCC did not or only very 
moderately differ among HCC etiologies. However, when we compared the immune contexture of different HCC 
tumour stages, we observed the selective reduction of (CD8+) T cells and dendritic cells, which was accompanied 
by an increase in T helper cells and a decrease in cytolytic and co-stimulatory activity in samples from more 
advanced patients. This clearly indicates that HCC gradually loses the ability to mount an effective Th1 and cytol-
ytic immune response upon disease progression. Of note is also that the expression profiles for 18 immune cell 
types remained unchanged across different tumour stages. The lack of major alterations in 18 immune cell subsets 
Figure 5. An immune gene signature comprising marker genes for T cells, cytotoxic cells, Th2 cells and 
macrophages predicts survival in HCC patients. (A) Kaplan-Meier analysis showing the differential survival of 
the TCGA HCC patient cohort according to the novel immune gene-based prognostic score. The prognostic 
score was defined using previously identified immune cell type gene sets (T cells, cytotoxic cells, Th2 cells and 
macrophages). Groups of patients with predicted good and poor survival were built based on the gene-wise 
statistics of the proportional hazards model (Fig. 4B) using a scoring system. Kaplan-Meier estimators were 
calculated for both groups. Significance in differential survival between both groups was determined using a 
log-rank test. (B) Validation of the gene signature in an independent set of HCC samples confirmed that this 
score distinguishes between patients with good and poor survival. All analyses were conducted as in “A”.
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between early and late HCCs suggests that these cells are not relevant for tumour progression. However, since 
the here applied immune cell-specific gene sets were limited to 24 major immune cell types, our analysis may not 
have recognized differences in more specialized immune cell subtypes such as differently polarized macrophages 
or myeloid-derived suppressor cells, that are known to be mechanistically linked to HCC tumour progression 
and stage31–33. In the future, gene sets for these cell types have to be defined yielding additional insights about the 
correlation of such subsets with HCC tumour stage and progression.
Another question our study cannot address due to lacking clinical information is whether pre-treatment 
of HCC patients such as hepatic resection or transarterial chemoembolization affects the composition of the 
immune contexture. This remains to be uncovered and will likely impact future clinical trials investigating either 
different treatment sequences or combinations of locoregional approaches and immunotherapies. In this regard, 
the STORM trial, which had surprisingly not found a benefit for an adjuvant treatment with sorafenib after resec-
tion or ablation in HCC patients34, serves as a historical example of a study on the dependency between locore-
gional and adjuvant systemic treatment.
Our study also established a clear association between overall survival, the invasion of specific immune cells 
and the strength of immune activity patterns in HCC. Overall, we noticed a positive association of an immu-
nostimulatory TME with survival and vice versa. In this respect, we identified gene sets for T cells, CD8+ as 
well as cytotoxic cells, Th2 cells, NK cells, immature dendritic cells, macrophages, cytolytic activity and T cell 
co-stimulation that were associated with survival. Our findings thus extend and are directly supported by pre-
vious studies reporting superior survival rates in HCC patients with an inflammatory TME16 and vice versa in 
case of an immunosuppressive microenvironment35. In particular, tumour infiltration by T and NK cells26 as well 
as tumour-associated antigen-specific CD8+ T cell responses36 have been reported to correlate with survival in 
HCC. Our analysis thus provides clear additional evidence that the infiltration by Th1-type immune cells and the 
presence of a cytolytic TME are directly linked to a favourable clinical outcome.
Based on our findings, we introduce a novel prognostic scoring algorithm comprising immunological markers 
for T cells, cytotoxic cells, Th2 cells and macrophages. When validated using an independent HCC data set, this 
signature stratified patients according to survival suggesting the general utility of this signature for future appli-
cations. More importantly, our gene signature was more significantly associated with survival than the two sig-
natures published by Chew et al.16,26. The immune gene set simultaneously proposed by Llovet and colleagues27, 
which shares only 8 genes with the here established signature, achieved similarly high significance levels high-
lighting the appropriateness of using immune-related gene signatures to stratify patients.
Taken together, our study emphasizes the relevance of the immune TME for the outcome of human HCC and 
provides the first comprehensive report about the relevance of different immune cell subsets and immune activity 
patterns for this disease. The here presented bioinformatics approach also represents a straightforward methodology 
for analysing other human malignancies and will be highly useful for monitoring and guiding future clinical studies.
Methods
All statistical analyses were conducted within the statistical programming environment R (v3.3)37. The R-code 
used for the immune cell type marker enrichment analysis, the Cox regression, and the prognostic score is avail-
able through GitHub (https://github.com/ssehztirom/foerster-hess-immune-contexture-2018).
Gene expression data. Gene expression measured by mRNA-Seq in HCC from 371 patients is available in 
The Cancer Genome Atlas (TCGA). For 50 of these patients, gene expression measured in adjacent liver tissue is 
available (RNASeqV2; 2015/12/17). Gene expression data measured by mRNA-Seq in tumour-free post-mortem 
liver samples of 34 donors is available in the Genotype-Tissue Expression project (GTEx; v.4). Data was down-
loaded from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/; “…rsem.genes.results”) and from the 
GTEx portal (http://www.gtexportal.org/home/; “…gene_reads”). Venn diagrams were built for each group con-
sidering transcripts as being expressed when aligned gene reads were recorded in ≥10 out of 30 RNA-Seq libraries.
Merging of TCGA with GTEx data. To harmonize TCGA and GTEx data sets, GENCODE annotations (v.18) 
used for the quantification of the GTEx data were assigned to the corresponding UCSC gene annotations using the 
genome annotation file (GTF) provided by the GTEx project (gencode.v18.genes.patched_contigs.gtf). Merging GTEx 
and TCGA data resulted in 16,776 common gene annotations shared between both data sets (Supplementary Table 5).
Clinical data and subgroup definition. For each sample, donor characteristics were extracted from 
TCGA (biospecimen_sample_lihc.txt, clinical_patient_lihc.txt) as well as GTEx data sheets (GTEx_Data_2014-
01-17_Annotations_SampleAttributesDS.txt) and are listed in Supplementary Table S3. Since age was indicated 
in decades in the GTEx data set, patient age from the TCGA data was also stratified using 10 year periods as age 
classifiers. For statistical analysis, patients were grouped according to survival (<2, between 2 and 5 and >5 years; 
patients with a survival <30 days were excluded), known risk factors (alcohol abuse, hepatitis B, hepatitis C, hep-
atitis B and/or C and alcohol abuse, non-alcoholic steatohepatitis (NASH) and no risk factor (i.e patients for who 
the etiology was not clearly defined)) and TNM/UICC tumour stage (stage I, stage II and stage III & IV). Patients 
with incomplete medical information were excluded.
Detection of differential expression. Differential mRNA expression was inferred using linear models. 
For testing differential expression in the risk factor, survival and tumour stage subgroups, TCGA HCC samples 
were compared to healthy liver samples from GTEx. Age and gender were always included as covariates in addi-
tion to the factor of interest. Linear models were fit using limma (v3.28)38. After normalizing for sequencing 
depth, trimmed mean (TMM) normalization39 was implemented in EdgeR (v3.14)40. The limma routine “voom” 
was employed to log transform the RNA-Seq data and to estimate precision weights for each gene which were 
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used for improved accuracy of the linear model fitting in limma41. Pseudo-replication resulting from tumour 
samples and samples of adjacent liver tissue stemming from the same individual was addressed by estimating 
the intra-patient correlation of gene expression using the limma routine “duplicateCorrelation”. Differential 
expression was assessed using moderated t-tests. Genes that were differentially expressed at a false discovery rate 
(FDR) < 0.01 and a log2-fold change (FC) > 2 and <−2 were considered significant.
Immune cell type marker enrichment. For identifying different immune cell subsets and immune activ-
ity patterns, marker genes were retrieved from previous publications11,13 and are listed in Supplementary Table 6. 
Enrichment of these marker sets was determined using gene set enrichment analysis. To this end, the roast 
method42 implemented in limma38 was employed as it allows for enrichment testing between two groups based on 
a multivariate linear model. The linear models used for the univariate analyses (“Detection of differential expres-
sion”) were employed here. In particular, we tested, whether the mean t-statistic in a gene set that is characteristic 
for a specific immune cell type or a specific activity pattern was significantly shifted from zero in a two-group 
comparison. Significance was assessed by 10,000 random rotations of the residuals orthogonal to the adjustment 
variables and by comparing the observed mean t-statistic with the results obtained by the rotated residuals.
Cox regression to investigate the association of immune cell type marker gene expression with 
survival. For each marker gene in the immune marker gene list (see “Immune cell type marker enrichment”), 
association with survival was estimated. Cox proportional hazards models were fitted to the survival data stored 
in the TCGA using the “coxph” function from the “survival” package (v2.39). The expression of a marker gene 
was transformed using the voom transformation implemented in limma41 and entered the model as covariate. 
We adjusted for patient age (measured in decades) and gender. After the model fit, z-scores were computed for 
the gene expression variable. Consistent association with survival within a cell type-specific marker gene set was 
assessed by comparing the mean of the z-scores within a cell type-specific gene set with an empirical null distribu-
tion. The distribution was generated by sampling an equivalent number of z-scores from the total set of z-scores in 
the total immune cell marker gene set and calculating the mean z-score. Sampling was repeated 10,000 times and 
p-values indicate the proportion of sampled mean z-scores being more extreme than the observed mean z-scores.
Ingenuity Pathway Analysis®. The networks analyses were conducted with QIAGEN’s Ingenuity 
Pathway Analysis® (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). In all cases p-values and log2 
FCs of differentially expressed genes (FDR < 0.01 and log2 FC > 1 and <–1) were submitted to IPA®.
Building a prognostic score based on immune cell-type marker gene expression. Based on the 
results of the Cox regression performed with the TCGA data, immune cell groups were selected and the expres-
sion of the corresponding marker genes was aggregated using a scoring system. For each cell type marker gene, 
the individual patient’s score was increased by “1” if the expression was below the median when higher gene 
expression corresponded with higher risk or if the expression was above the median when higher gene expression 
corresponded with a lower risk. The prognostic score derived from the TCGA data was validated in an independ-
ent data set24. Survival probabilities were determined by the Kaplan-Meier method, and comparison between 
groups was performed by log-rank tests.
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